Aspen And Eli Lilly Sign US$1mn License Agreement

South African generic drugmaker Aspen Pharmacare has signed an agreement worth US$1mn with Eli Lilly to manufacture tuberculosis (TB) medicines, including one type specifically for patients with multi-drug resistant TB. BMI believes that the deal highlights Aspen's continued drive to engage in licence deals to bolster sales.

To read the full article, please choose one of the following options: